Floatz logo

RASDEGAFUSP ALFA

Advanced Triple Negative Breast Cancer

Case Comprehensive Cancer Centerprotein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

448 Active assets in the Advanced Triple Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

RASDEGAFUSP ALFA is also rated in:

melanomaDormant
BB
Indicative ·
64 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
61 / 100
View asset →
Recurrent Ovarian CarcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →